Many different types of soft and solid tumors have now been sequenced, and meta-analyses suggest that genomic variation across tumors scales with the stiffness of the tumors' tissues of origin. Vogelstein and Tomasetti recently suggested cancer risk scales sub-linearly with the normal rate of stem cell divisions in the tissue of origin, suggesting a key role for DNA replication in mutation processes, and multiple 'mechanogenomics' mechanisms might explain the additional scaling of mutation rate with tissue stiffness. Since stiff solid tissues have higher density of fibrous collagen matrix, which should decrease tissue porosity, processes in proliferation could be affected and so could invasion into stiff tissues as the nucleus is squeezed sufficiently to enhance DNA damage. Although careful analyses continue to be required for rigorous conclusions about such DNA damage, diversification of a cancer genome after constricted migration is now clear in vitro. Understanding genome changes that give rise to neo-antigens is important to selection of cancer cell subpopulations (immunoediting) as well as to the development of immunotherapies. Monocytes/macrophages that might now be engineered to effectively attack cancer cells seem particularly relevant to understanding infiltration into solid tumors and the effects of microenvironment stiffness on genes such as the nuclear lamins.
Introduction
Tumors are often palpably stiffer than nearby normal tissue [1] , with stiffness of breast and liver, among other organs, correlating with cancer risk [2, 3] . Tissue stiffness likely contributes in normal cells to motility [4] and differentiation [5] , and in cancer cells to invasion [6] and various epigenetic mechanisms [7] , including stiffness-dependent nuclear localization of oncogenic factors (e.g. YAP) [8] . It is unclear, however, if a physical attribute of the microenvironment such as stiffness could contributedin a 'mechanogenomics' type of processdto any of the many genetic changes that typically occur in cancer.
Meta-analyses of recently published cancer mutation data begin to suggest thatdbeyond some initial driver mutation(s)dthe large genomic variation across diverse cancers scales with stiffness of the normal tissue of origin. Stiffness-dependent cell biological mechanisms for genome variation are needed to establish any causality, and some molecular mechanisms are now emerging. We focus on one possible mechanism based on the fact that stiffer tissues, including tumors, are enriched in collagen [9] , and many studies of collagen gels show that denser collagen has smaller matrix pores (e.g. Ref. [10] ). Thus, as cancer cells proliferate and/or invasively migrate into stiff, small-pore surroundings, the DNA can be damaged, which might ultimately contribute to genomic diversity.
Invasion and proliferation are defining tasks of any malignant cell; the equal but opposite challenge of an immune celldtherapeutic or otherwisedis to squeeze if possible through tissue barriers and infiltrate a wound or disease site in order to attack 'non-self '. In the cancer context, genome variation can produce novel protein sequences that might be perceived by the immune system as 'neo-antigens'. Such sequences are by definition absent from normal cells, and so can be used to identify and eliminate (immune-edit) cancerous cells if the neo-antigen signals are sufficiently potent, accessible, and foreign to overwhelm 'self ' recognition [11] . A moonshot-scale effort now seeks to employ neo-antigens in various immunotherapy approaches. Some therapies use engineered T-cells to target neo-antigens on the cancer cell membrane [12] , while other therapies exploit the major histocompatibility complex (MHC)dclass I and class IIdto target nuclear and cytoplasmic neo-antigens [13e15] . Monocytes and macrophages are the focus here and are particularly interesting for targeting to neo-antigens because these phagocytic cells exhibit the most robust ability to infiltrate solid tissues, including tumors. As will be illustrated, the microenvironmentdependent plasticity of such cells, which is now being mapped by modern systems biology methods, could also be triggered, in part, by the stiffness or solidity of the tissue.
Genomic variation scales with tissue stiffness
Advances in genome sequencing have enabled cataloguing of the genomic variations that occur in cancers of many different types [11, 16, 17] , and although oxidation artifacts can complicate such methods [18] , somatic mutation rates are being collected in databases such as The Cancer Genome Atlas (TCGA) run by the National Cancer Institute (NCI). For the healthy tissues of origin of 36 types of cancer, tissue microelasticity data were culled from numerous recent papers [11,19e38] that used a variety of physical methods, including atomic force microscopy (AFM), micro-indentation probes, micropipette aspiration, and imaging-based elastography (Table 1) . Whereas AFM pushes on cells and tissues at the w100-nm to multi-micron length scales in order to provide a measure of a microenvironment's stiffness, the larger length scale imaging-based elastography methods that perturb and monitor by magnetic resonance imaging, for example, typically probe on a millimeter length scale. The latter encompasses many cells and the matrix between them; in principle, all of these types of measurements should be made on fresh tissue, since the former add up to the latter. However, measurements on cultured cells are likely to have little relevance to the tumor, because culture conditions such as gel stiffness influence cell mechanics [5] . Based on current tissue measurements, meta-analyses of genomics indicate that cancers arising in tissues that are normally stiff to withstand mechanical expansion and distension, such as lung and skin, exhibit 30-fold higher somatic mutation rates (as median per sequenced megabase) than cancers arising in soft tissues, such as marrow and brain ( Figure 1A) . Importantly, the stiffness of a typical brain tumor or marrow tumor never increases to that of a typical bone tumor microenvironment even though tumors often stiffendor, less frequently, softendin tumorigenesis [1] . Accounting for tissue-dependent replication rates in the normal tissues (again) will no doubt be important as discussed below, but the normal hierarchy of tissue stiffness seems crucial, with brain being softer than liver, which is softer then bone, etc.dregardless of cancer or not.
Childhood muscle and bone cancers have only slightly elevated somatic mutation rates as compared to childhood marrow and brain cancers, but they have >10-fold more chromosome copy number changes and structural variants [23] ( Figure 1B ). This disparity suggests that large-scale, chromosome-level amplifications and deletionsdmore so than somatic mutationsdare signatures of some mutational processes that associate with tissue stiffness. In adult melanoma, fibrotic skin tends to be stiffer and exhibit more chromosome copy number changes than softer, less fibrotic skin [24, 39] (Figure 1C-i) . Moreover, these copy number changes increase even faster with stiffness than do somatic mutation rates, and all mutations are most abundant in invasive melanoma [24] (Figure 1C-ii) . The relationship between chromosome-level mutations and stiffness thus holds even within a given tissue type, suggesting a correlation between mutations and stiffness that cannot be entirely explained away by exposure to carcinogens. Mechanical causes of mutation underlie genomic variation with tissue stiffness
Scaling of genomic variation with tissue stiffness could result from at least three possible mechanical sources of mutations. First, relative to a very soft matrix, stiff matrix can sometimes enhance cell proliferation, as has been shown by an increase in BrdU incorporation with substrate stiffness in 2D cultures of normal human smooth muscle and breast epithelial cells as well as mouse embryonic fibroblasts [40] . DNA replication in each cell division cycle carries with it some risk of spontaneous mutation [20, 41] , accounting for about 67% of mutations in human cancers [42] . Since these mutations accumulate over successive generations, more proliferation should mean more changes to the genome. Tomasetti and Vogelstein have correlated cancer risk with the division rates of stem cells estimated in normal tissue (R 2 w 0.6e0.7). Interestingly, if one excludes cancers with deterministic origins such as smoking, then it is evident that tissues which are normally stiff and resilient such as skin and lung exhibit greater risk than softer tissues having similar division rates. Nowak and Waclaw [43] also pointed out for the case of one-hit, oncogenic initiation that cancer risk scales (again in logelog plots) with the division rate of the resident tissue stem cells with a power law of 0.53, which is lower than linear scaling as expected for a simple stem cell contribution [42] . Tissue geometry was speculated to suppress the 'effective number of stem cell divisions' [43] . More study is thus needed, especially in 3D, because a 3D stiff surrounding is likely to physically impact the fidelity of replication and chromosome segregation during mitosis.
A second conceivable explanation for the scaling relationship is that stiffness increases the frequency of Genomic variation increases versus tissue stiffness across cancers and with melanoma progression. (A) Across different cancer types, somatic mutation rate-the median number of somatic substitutions and small insertions/deletions per megabase-increases with normal tissue stiffness. The same trend persists, albeit more weakly, among childhood cancers. The stiffness scale varies >10-fold from softer tissues (green), such as marrow and brain, to stiffer tissues (red), including lung, skin, muscle, and bone. (B) Large-scale, chromosome-level mutations likewise increase with stiffness: childhood cancers in stiffer tissues have 10-to-20-fold more chromosome copy number changes and structural variants than do cancers in softer tissues, while somatic mutation rates differ much less. (C) (i) Melanomas from patients of 60 years have fewer copy number changes than melanomas from patients over 60. The younger patients also have softer, less fibrotic skin, as inferred from their lower average solar elastosis score; solar elastosis is the thickening of skin due to prolonged sun exposure. (ii) In skin cancer genomes, chromosome copy number changes increase strongly with somatic mutation rate and lesion stiffness, with all highest in "invasive melanoma". nuclear envelope rupture [44] . Such rupture causes transient leakage into the nucleus of cytoplasmic factors, including perhaps nucleases per recent speculations [45] , which might damage DNA and contribute to genome instability. However, the increase of rupture frequency with substrate stiffness has been observed only in cells with defects in lamin-A, which is one of the three intermediate filament proteins that confer strength and stability to the nucleus. Yet, cancer types vary widely in their lamin-A expression levels: it is downregulated in leukemia as well as in breast and lung cancers, whereas it is upregulated in colorectal and skin cancers (for review: [46] ). Lamin-A is highly mutated in multiple laminopathies, but cancer risk is not reported to be elevated. The inconsistency in lamin-A levels across cancer types argues against a simple stiffness-induced nuclear rupture hypothesis even though studies of rupture are likely to be revealing of basic mechanisms.
A third explanation that we find more promising is based on invasion of cells through stiff tissues, given that invasion is a 'hallmark' of cancer. Tissue stiffness increases with fibrous protein (e.g. collagen) concentration [9] , which, in turn, anti-correlates with extracellular matrix pore size [10] (Figure 2A ). Hence, cancer cells invading normal tissue, as during tumor growth [47] , encounter higher collagen matrix levels and smaller pores in stiffer tissues than in softer ones [48] . Importantly, the recent studies of DNA damage incurred during constricted migration also provided the first evidence of propagatable mutations. The genomes of serially migrated clones were analyzed by comparative genome hybridization arrays (aCGH), single-nucleotide polymorphism arrays (SNPa), and whole-exome sequencing (as well as RNA sequencing). Compared to unmigrated control clones or even cells that migrated through large pores, the cells that squeezed through very small, blood capillary-sized pores exhibited elevated chromosome copy number changes [54] , suggesting that such chromosome-level abnormalities are characteristic of constricted migration. Recall that our meta-analysis showed that copy number changes and structural variants scale with normal tissue stiffness, perhaps more so than somatic mutations ( Figure 1B and C) . Hence, constricted migration and stiffness seem to share a mutational signature, namely large-scale genome instability. This signature also resembles that of osteosarcomas and breast and ovarian cancers with BRCA deficiencies [55] , although more such analysis is needed. Taken together, these genomic analyses hint at a connection between stiffness, constricted migration, and repair factor depletion ( Figure 2C) . Thus, these studies tentatively support the hypothesis that loss of DNA repair during migration of cancer cells through small pores in fibrous matrix could underlie the scaling relation between mutation rate and tissue stiffness (Figure 1 ).
Genomic variation gives rise to targetable neo-antigens
Genome changes, including those induced by a stiffness-related mechanism, can affect gene expression and lead to protein changes, which can contribute to a cancerous phenotype or merely be recognizable passenger mutations [11, 16, 17] . For example, in our studies of genome variation caused by constricted migration, one clone acquired after migration a spindle shape and migrated through pores much faster than other clones. Further experiments attributed this distinct phenotype to upregulation of the transcription factor GATA4 [54], which influences a program for microtubule organization. Microtubules are well known to be the most rigid polymers in cells and help direct cell migration.
Stiffness can also directly affect the expression of genes, so in a cancer like melanoma where tissue stiffness increases with invasiveness ( Figure 1C ), some genes are expected to be upregulated. If these genes are also mutateddby a 'mechanogenomics' process or otherwise, then they could present neo-antigens to the immune system. Neo-antigens, or altered proteins, are 'foreign' in being distinct from anything in healthy cells and can thus be used therapeutically to target diseased cells. As an example, tissue stiffness causes systematic upregulation of lamin-A over a 20-to-30-fold range [9] ( Figure 2B ). Mutations in lamin-A have been reported in The Cancer Genome Atlas (TCGA): one case study showed about 4% of 287 melanoma patients exhibited either amplifications (2%) or mis-sense passenger mutations (2%) in lamin-A's coding sequence, with no statistically significant impact on patient survival (http:// bit.ly/2oUMGyL). Lamin-A is nonetheless one conceivable source of neo-antigen thatdwhen mutateddassociates with tissue stiffness. Future studies of such upregulated, mutated genes should yield other candidates.
Efforts to therapeutically target neo-antigens, including those that arise in a stiffness-dependent way, are complicated by intratumor heterogeneity: different cells from a single tumor have been found to vary widely in their somatic mutations [20, 56] . This heterogeneity reduces the probability of finding a ubiquitous, targetable mutation present in all of a patient's cancer cells. [63] , which yield similar abnormal protein phenotypes, but changes can vary between patients. Hence, therapies for different patients must target different peptide sequences [11, 64, 65] . This variability makes it necessary to isolate and sequence every individual tumor to identify its unique neo-antigen profile, which remains a resourceintensive challenge for current sequencing [66] . If the technology continues to advance, it is exciting to consider that personalized neo-antigen-based therapy could enter clinical practice [67, 68] .
Diverse neo-antigen-based immunotherapies are currently under development
Neo-antigen-based therapies can take various approaches. Some therapies target proteins expressed on the plasma membrane, relying on surface protein expression level to distinguish cancerous cells from healthy ones. In one of the most-used such therapies, chimeric antigen receptor (CAR) T cells target the Blymphocyte antigen CD19 [12] . While CD19 is expressed on over 95% of B-cell malignancies, it is also expressed on healthy B cells, making the latter susceptible to off-target effects [69] . However, the ongoing discovery of surface neo-antigens, such as mucin-1 (MUC1, which is also in the extracellular matrix and leaks into serum), that have irregular glycosylation patterns in cancer cells makes it possible to engineer CARs to target these unique glycosylations, thus minimizing deleterious side effects [70, 71] . Most neo-antigens are not expressed on the plasma membrane, but rather in the nucleus or cytoplasm of the cell [72] , so chemotherapeutics, which readily penetrate the cell membrane, can be effective against them. However, chemotherapeutic agents are difficult to modify against different peptide sequences since any change in their structural chemistry can radically alter pharmacokinetics. Although the chemotherapy drug Vemurafenib effectively targets the BRAF V600 mutation, it is ineffective against other BRAF mutations [73, 74] , which reinforces the need to identify each patient's unique mutation profile.
Other approaches use nuclear and cytoplasmic neoantigens to develop vaccines and checkpoint inhibitors [13] . These approaches take advantage of the major histocompatibility complex class I (MHC I), which presents peptide fragmentsd8-10 amino acids longdthat are continuously screened by the immune system for foreign peptide sequences [75] . Unfortunately, mutated peptide sequences in cancerous cells often go undetected because they either have poor MHC I affinity, differ little from their wild-type counterparts, or are abetted by high levels of the cancer cell-derived immune inhibitory ligand PD-L1 [17,76e80] . PD-L1 inhibitors can counteract this tumor-induced immune suppression [81] . Sequencing is now being used to identify cancerous mutations in oncogenic drivers like KRAS and p53 and that might also have high MHC I affinity as needed for anti-cancer vaccines [82, 83] .
An alternative vaccination approach exploits MHC class II molecules expressed by macrophages [14, 15] . Like MHC I, MHC II presents peptide fragments at the cell surface. But whereas detection of a foreign sequence triggers cell destruction by the immune system in the MHC I case, it triggers activation of the adaptive immune systemdagainst other cells weakly presenting that same foreign sequencedin the MHC II case. Macrophages use MHC II to present peptide sequences from foreign organisms or viruses that they have phagocytosed. Unfortunately, macrophages do not engulf cancer cells in part because the latter express the ubiquitous 'marker of self' CD47 [84] , which binds the macrophage receptor SIRPa in a 'phagocytic synapse' and then signals inhibition of phagocytosis [85] . Macrophages in tumors might have little to no impact on tumor growth after injection of anti-(mouse CD47) [86] , and if true this would preclude a role for MHC II on these particular cells. However, macrophages have long been engineered ex vivo for anti-cancer purposes and can be made to express patient-specific cancer neoantigen peptide sequences loaded into MHC II [15] . Upon injection back into the patient, these engineered macrophages activate the immune system against cancer cells that display the special peptide sequence. Numerous clinical trials conducted over the past two decades demonstrate that adoptive transfer of macrophages into humans shows little to no toxicity but also little to no efficacy at doses up to 1.5 billion cells [87e89]. To achieve some efficacy, macrophages might be antibodytargeted to common neo-antigens on tumors and also have their SIRPa inhibited or deleted before being injected; this approach could also prove safer than systemic inhibition of CD47, which leads to rapid loss of red blood cells (RBCs) [84] and in some mice to autoimmune responses including production of anti-RBC antibodies [90] .
One new macrophage-based therapy aims to exploit neoantigens without the need for extensive sequencing or artificial targeting vectors (e.g. CARs). Tumor associated macrophages (TAMs) can, through inhibition of CD47, phagocytose cancer cells [91] , and then present neoantigens from those cells to activate the adaptive immune system [86, 92] . However, TAMs promote tumor growth, are weakly phagocytic even with CD47 disruption, and have low MHC II expression, which hinders their ability to activate an adaptive immune response [15, 93, 94] . Instead, a cell therapy approach might use fresh, marrow-derived monocytes and macrophages with high-affinity antibody inhibition by SIRPa combined with at least one initial cancer-targeting antibody, because neo-antigens might exploit high MHC II expression on the marrow-derived cells [95] . In addition, marrow-derived monocytes and macrophages are highly migratory and can infiltrate solid tumors [96] ( Figure 3A) . However, like cancer cells invading nearby tissue, these 'invading' immune cells might also suffer DNA damage. The absence of oncogenic driver mutations probably limits the cancerous potential of infiltrating monocytes and macrophages; any DNA damage in these cells might instead contribute to senescence [97] or perhaps differentiation.
Lastly, while novel cell therapy approaches with infiltrating immune cells seems an encouraging but challenging direction for the field of neo-antigen-based immunotherapy, the microenvironment-dependent plasticity of such cells is also emerging from modern systems biology methods ( Figure 3B ) and must be factored into cell function. Interestingly, for monocytes and macrophages, at least some genes in published profiles (e.g. lamin-A but not lamin-B1) increase with tissue stiffness (marrow w brain < liver < spleen < lung), consistent with mechanically regulated epi-genetic processes in a wide range of tissue cells [9] and likely also in cancer cells [7, 8] . Further RNA profiling of tissue macrophages, including TAMs, needs to be done using identical markers across different tissues, as macrophage transcriptomics would be expected to change when sorted on different markers ( Figure 3B ).
Conclusion
The meta-analysis here of recently published sequencing data reveals that somatic mutation rate increases with normal tissue stiffness across cancer types, while the rate of larger-scale, chromosome-level mutations increases even faster. Among various hypotheses that seek to explain this scaling relationship, the one that we consider most promising holds that stiffer tissues have smaller extracellular matrix pores, which can increase DNA damage in invading cancer cells, leading perhaps to genomic variation. In the case of immune cells that might infiltrate solid tumorsdand go on to recognize neo-antigensdsuch healthy cells lack driver mutations and are unlikely to become oncogenic, but they can be expected to differentiate, perhaps even in relation to tissue stiffness. DNA damage follows repair factor depletion and portends genome variation in cancer cells after pore migration. Curr Biol 2017, 27:210-223. The authors demonstrate constricted migration causes DNA damage in a mechanism consistent with repair factor loss. DNA damage is measured by three different, standard approaches, and DNA repair factors are shown to be mis-localized with respect to chromatin. This is the first paper to document genomic changes in cell migration. 
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